STOCK TITAN

BVF Group Discloses Convertible Stakes in Eledon (ELDN) — 9.99% Blockers

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Eledon Pharmaceuticals: Schedule 13G/A filing reporting aggregated beneficial ownership by Biotechnology Value Fund group. As of the close of business on March 31, 2026, the Reporting Persons and a Partners managed account hold convertible securities and warrants that, subject to multiple 9.99% ownership blockers, translate into convertible and exercisable positions described below.

The filing lists aggregate holdings including 5,382,084 Shares beneficially owned by BVF, 2,057,090 Shares by BVF2, and various convertible instruments: 4,419.93 shares of Series X Preferred (convertible into 245,552 Shares), 87,607.152 shares of Series X1 Preferred (convertible into 4,867,067 Shares), 15,247,782 Pre-Funded Warrants (exercisable into 15,247,782 Shares), and 5,844,153 Tranche A Warrants. The filing explains conversion/exercise blockers that currently limit conversion or exercise into Shares.

Positive

  • None.

Negative

  • None.

Insights

BVF group discloses complex convertible positions constrained by multiple 9.99% blockers.

The filing enumerates convertible preferreds, pre-funded warrants and Tranche A warrants with explicit anti‑beneficial‑ownership limits tied to a 9.99% threshold. These provisions currently prevent conversion or exercise into additional Shares as of March 31, 2026.

Cash‑flow treatment and exact timing of any conversions or exercises depend on holder decisions and the operation of the stated Blocker provisions; subsequent filings would disclose any conversion activity or changes in the denominator used to compute ownership percentages.

The statement carefully attributes shared/disclaimed beneficial ownership across related entities.

BVF, BVF2, Trading Fund OS and affiliated entities are presented with shared voting/dispositive power figures and disclaimers; several entities "may be deemed" to beneficially own aggregated positions while contemporaneously disclaiming beneficial ownership of others.

Read together, the disclosures aim to satisfy Schedule 13G/A aggregation and attribution rules; monitor future amendments if any blocker conditions change or if exercises occur.

Shares outstanding (denominator) 75,851,722 shares as of March 13, 2026
BVF beneficially owned 5,382,084 Shares as of March 31, 2026
BVF2 beneficially owned 2,057,090 Shares as of March 31, 2026
Pre‑Funded Warrants held 15,247,782 warrants exercisable into 15,247,782 Shares at $0.001/share
Tranche A Warrants held 5,844,153 warrants exercisable at $3.00, expire May 5, 2028
Series X Preferred held 4,419.93 shares convertible into 245,552 Shares (55.5556 per preferred)
Common ownership cap 9.99% blocker limiting conversions/exercises stated throughout filing
Pre‑Funded Warrant financial
"Each Pre‑Funded Warrant is exercisable immediately, has an exercise price per Share of $0.001"
Series X Preferred financial
"As of the close of business on March 31, 2026, the Reporting Persons held an aggregate of 4,419.93 shares of Series X Convertible Preferred"
Blocker regulatory
"The Series X Preferred may not be converted if, after such conversion, the Reporting Persons would beneficially own... more than 9.99% (the "Series X Blocker")"
Tranche A Warrant financial
"The Tranche A Warrants are exercisable at any time at a price of $3.00 per Share and expire on May 5, 2028"





28617K101

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:05/15/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:05/15/2026

FAQ

What stake does Biotechnology Value Fund (BVF) report in Eledon (ELDN)?

BVF reports beneficial ownership of 5,382,084 Shares, representing approximately 6.8% of outstanding Shares as of the filing's denominator. The figure includes 1,575,137 Shares underlying certain Pre‑Funded Warrants counted for BVF.

How many Pre‑Funded Warrants does the BVF group hold and what limits apply?

The Reporting Persons hold 15,247,782 Pre‑Funded Warrants exercisable into the same number of Shares at $0.001 per Share. A Pre‑Funded Blocker limits exercise so beneficial ownership would not exceed 9.99%.

What convertible preferred positions are disclosed in the filing?

The group holds 4,419.93 shares of Series X Preferred (convertible into 245,552 Shares) and 87,607.152 shares of Series X1 Preferred (convertible into 4,867,067 Shares), each subject to a 9.99% conversion blocker.

What ownership percentages do affiliated entities report?

As of the filing denominator, BVF reports ~6.8%, BVF2 ~2.7%, BVF GPH ~9.4%, and Partners, BVF Inc., and Mr. Lampert each may be deemed to beneficially own ~9.99% of outstanding Shares.

Are the Tranche A Warrants currently exercisable into Shares?

The Reporting Persons hold 5,844,153 Tranche A Warrants exercisable at $3.00 per Share through May 5, 2028, but a stated Tranche A Blocker currently prohibits exercise into Shares for the reported holdings.